AAN 2023

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

01:00 PM

Duration 12mins S5: Autoimmune Neurology: NMOSD and MG, A Focus On Treatment Trials

Long-term efficacy of satralizumab▼ in adults with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): Results from the roll-over, open-label study SAkuraMoon

A Traboulsee, I Kleiter, J Palace, K Fujihara, A Saiz, I Vodopivec, G Klingelschmitt, C Marcillat, J L. Bennett

Neuroscience | Neuromyelitis Optica

02:48 PM

Duration 12mins S2:Child Neurology and Developmental Neurology

MANOEUVRE study design: A study of GYM329 (RO7204239) in patients with facioscapulohumeral muscular dystrophy (FSHD)

Statland J, Eichinger K, Morrow JM, Tasca G, Vissing J, Dodman A, Jaber B, Kletzl H, McIver T, Scalco RS, Yeung WY, Gaki E, Wagner KR

Neuroscience | facioscapulohumeral muscular dystrophy

12:09 PM

Duration 7mins ES1: Emerging Science 1

Peripheral Blood Gene Expression Transcriptional Profiling Predicts Disease Progression in Primary Progressive Multiple Sclerosis

Gurevich M, Zilkcha-Falb R, Sonis P, Magalashvili D, Menascu S, Dolev M, Achiron A

Neuroscience | Multiple Sclerosis

01:24 PM

Duration 12mins S16: MS Clinical Trials and Therapeutics

Immunological Signatures Associated With Ocrelizumab▼ Treatment in Early RRMS: 12-Month Interim Analysis From the Ocrelizumab▼ Phase IIIb (ENSEMBLE; NCT03085810) Immunological Sub-study

Wirth T, Schulte-Mecklenbeck A, Steinberg OV, Raposo C, Gross CG, Wiendl H, Klotz L

Neuroscience | Multiple Sclerosis

02:00 PM

Duration 12mins Boston Convention and Exhibition Center - 252AB

Enabling subcutaneous dosing of gantenerumab▼ in Alzheimer’s disease

Bittner B, Schwab D, Lott D, Boess F, Kohler R, Portron A, Wojtowicz J, Hofmann C

Neuroscience | Alzheimer's Disease

02:48 PM

Duration 12mins Boston, USA / Virtual (Hybrid)

EXPECTED VS DIAGNOSED RATES OF MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN THE US MEDICARE POPULATION

Mattke S, Jun H, Chen E , Liu Y, Becker A, Wallick C

Neuroscience | Alzheimer's Disease

02:00 PM

Duration 12mins S26: Experimental Therapeutics in Dementia

ALUMNI AD STUDY DESIGN:Evaluation of Subcutaneous Gantenerumab in Historically Underrepresented US Populations With Early Symptomatic Alzheimer’s Disease

Seleri Assuncao S, Brangman S, Henderson J, Parker M, Monroe S, Mintzer J, Wise-Brown A, Grundman M, Smith J, Doody R, Lin H, Assman B, Rippon G

Neuroscience | Alzheimer's Disease

02:48 PM

Duration 12mins Boston Convention and Exhibition Center - 151AB

GRADUATE I and II: Findings of Two Phase III Randomized Placebo-controlled Studies Assessing the Efficacy and Safety of Subcutaneous Gantenerumab▼ in Early Alzheimer’s Disease (AD)

Smith J, Donohue MC, Gruendl E, Grimmer T, Perry RJ, Black SE, Salloway S, Lyons M, Rutten-Jacobs L, Bittner T, Blennow K, Pelentrides C, Barkhof F, Tonietto M, Baudler-Klein M, Fontoura P, Doody RS

Neuroscience | Alzheimer's Disease

04:30 PM

Duration 12mins S31: MS Clinical Decision Making and Special Populations

An Interim Analysis of Efficacy and Safety Data in Black and Hispanic Patients With Multiple Sclerosis Receiving Ocrelizumab▼ Treatment in the CHIMES Trial

Bernitsas E, Reder AT, Chinea A, Herrman C, O’Brien BC, Sater RA, Amezcua L, Williams MJ, Wu GF, Vartanian T, Pei J, Acosta J, Monson NL

Neuroscience | Multiple Sclerosis

02:36 PM

Duration 12mins S34:Child Neurology and Developmental Neurology

SUNFISH Parts 1 and 2: 4-year efficacy and safety of risdiplam▼ in Types 2 and 3 spinal muscular atrophy (SMA)

L Servais, M Oskoui, J W Day, N Deconinck, E S Mazzone, A Nascimento, K Saito, C Vuillerot, G Baranello, O Boespflug-Tanguy, N Goemans, J Kirschner, A Kostera-Pruszczyk, J Braid, G Papp, K Gorni, C Martin, R S Scalco, W Y Yeung, E Mercuri

Neuroscience | Spinal Muscular Atrophy

01:12 PM

Duration 12mins S46: MS Therapeutics and Clinical Decision Making

Long-term Treatment with First-Line Ocrelizumab▼ in Patients with Early RMS: 9-Year Follow-Up Data From the OPERA Trial

Cerqueira J, Berthele A, Cree BAC, Filippi M, Pardo G, Pearson O, Traboulsee A, Ziemssen T, Vollmer T, Bernasconi C, Mandel C, Kulyk I, Chognot C, Schneble H-M, Prajapati K, Havrdova EK

Neuroscience | Multiple Sclerosis

01:24 PM

Duration 12mins S46: MS Therapeutics and Clinical Decision Making

Delayed Signs of Early Disability Progression After 8.5 Years of Ocrelizumab▼ Treatment in Patients With Relapsing Multiple Sclerosis

Weber MS, Kappos L, Hauser SL, Schneble HM, Wang Q, Giovannoni G

Neuroscience | Multiple Sclerosis

01:36 PM

Duration 12mins S46: MS Therapeutics and Clinical Decision Making

Low Disease Activity Over 4 Years of Ocrelizumab▼ Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE Study

Bermel R, Hartung HP, Brochet B, Benedict R, Berger T, Carroll W, Vollmer T, Holmøy T, Karabudak R, Killestein J, Nos C, Patti F, Perrin Ross A, Vanopdenbosch L, Wuerfel J, Kuenzel T, Kadner K, Kulyk I, Freedman M

Neuroscience | Multiple Sclerosis

03:54 PM

Duration 12mins Session S48: Therapeutics for Muscle Disease

One-year Data from ENDEAVOR, a Phase 1b Trial of Delandistrogene Moxeparvovec (SRP-9001) in Patients with Duchenne Muscular Dystrophy (DMD)

Craig Zaidman, Crystal Proud, Craig McDonald, Stefanie Mason, Maitea Guridi, Shufang Wang, Carol Reid, Eddie Darton, Christoph Wandel, Sarah Lewis, Jyoti Malhotra, Danielle A. Griffin, Rachael A. Potter, Louise R. Rodino-Klapac, Jerry R. Mendell

Neuroscience | Duchenne Muscular Dystrophy

04:06 PM

Duration 12mins Session S48: Therapeutics for Muscle Disease

A Phase 2 Clinical Trial Evaluating the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Patients with Duchenne Muscular Dystrophy (DMD)

Perry B. Shieh, Mendell JR, Sahenk Z, Lehman KJ, Lowes LP, Reash NF, Megan A. Iammarino, Lindsay N. Alfano, Brenna Sabo, Jeremy D. Woods, Christy L. Skura, Howard C. Mao, Loretta A. Staudt, Rachael A. Potter, Danielle A. Griffin, Sarah Lewis, Larry Hu, Teji Singh, Louise R. Rodino-Klapac

Neuroscience | Duchenne Muscular Dystrophy

04:18 PM

Duration 12mins S49: General Neurology

Telemedicine Use Before and During the COVID-19 Pandemic Among People With Neurological Disorders: a Cross-Sectional Study Using US Commercial Claims Data

AM Patel, R Schuldt, DM Boudreau, N Win, BR Cobb, M McGinley.

Neuroscience | Neurodegenerative Diseases

04:30 PM

Duration 12mins Session S48: Therapeutics for Muscle Disease

Integrated Analyses of Data from Clinical Trials of Delandistrogene Moxeparvovec (SRP-9001) in Duchenne Muscular Dystrophy (DMD)

Craig Zaidman, Perry B. Shieh, Crystal Proud, Craig McDonald, John W. Day, Stefanie Mason, Maitea Guridi, Lixin Han, Lixi Yu, Carol Reid, Eddie Darton, Christoph Wandel, James Richardson, Jyoti Malhotra, Teji Singh, Louise R. Rodino-Klapac, Jerry R. Mendell

Neuroscience | Duchenne Muscular Dystrophy

I am a healthcare professional

Notice

Cookies

External site

AAN 2023